KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 227 filers reported holding KITE PHARMA INC in Q2 2017. The put-call ratio across all filers is 0.38 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $85,494,000 | +80.2% | 475,472 | +3.9% | 0.03% | +68.4% |
| Q2 2017 | $47,449,000 | +46.3% | 457,702 | +10.8% | 0.02% | +46.2% |
| Q1 2017 | $32,427,000 | +109.6% | 413,148 | +19.8% | 0.01% | +85.7% |
| Q4 2016 | $15,469,000 | -13.5% | 345,003 | +7.7% | 0.01% | -22.2% |
| Q3 2016 | $17,887,000 | +13.9% | 320,221 | +2.0% | 0.01% | 0.0% |
| Q2 2016 | $15,703,000 | +21.0% | 314,073 | +11.1% | 0.01% | +28.6% |
| Q1 2016 | $12,983,000 | -21.5% | 282,806 | +5.4% | 0.01% | -22.2% |
| Q4 2015 | $16,540,000 | +22.4% | 268,426 | +10.6% | 0.01% | +12.5% |
| Q3 2015 | $13,512,000 | +106.9% | 242,676 | +126.6% | 0.01% | +100.0% |
| Q2 2015 | $6,530,000 | +36.0% | 107,110 | +28.6% | 0.00% | +33.3% |
| Q1 2015 | $4,803,000 | +21.3% | 83,282 | +21.3% | 0.00% | +50.0% |
| Q4 2014 | $3,958,000 | +248.1% | 68,641 | +72.0% | 0.00% | +100.0% |
| Q3 2014 | $1,137,000 | – | 39,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |